Genus plc

OTCPK:GENS.F Stock Report

Market Cap: US$1.5b

Genus Valuation

Is GENS.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GENS.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$25.81
Fair Value
13.2% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: GENS.F ($22.4) is trading below our estimate of fair value ($25.81)

Significantly Below Fair Value: GENS.F is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GENS.F?

Key metric: As GENS.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GENS.F. This is calculated by dividing GENS.F's market cap by their current earnings.
What is GENS.F's PE Ratio?
PE Ratio148.5x
EarningsUK£7.90m
Market CapUK£1.17b

Price to Earnings Ratio vs Peers

How does GENS.F's PE Ratio compare to its peers?

The above table shows the PE ratio for GENS.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49x
MDXG MiMedx Group
15.4x-1.9%US$1.2b
DVAX Dynavax Technologies
84.4x33.4%US$1.7b
MNKD MannKind
72x34.1%US$1.6b
ACAD ACADIA Pharmaceuticals
24x24.9%US$3.2b
GENS.F Genus
148.5x37.2%US$1.2b

Price-To-Earnings vs Peers: GENS.F is expensive based on its Price-To-Earnings Ratio (148.5x) compared to the peer average (49x).

Price to Earnings Ratio vs Industry

How does GENS.F's PE Ratio compare vs other companies in the US Biotechs Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.7x-56.1%US$7.91b
AGIO Agios Pharmaceuticals
2.8x-29.7%US$1.96b
INBX Inhibrx Biosciences
0.1x-135.7%US$187.46m
CTMX CytomX Therapeutics
4.8x-13.8%US$68.09m
GENS.F 148.5xIndustry Avg. 17.5xNo. of Companies10PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GENS.F is expensive based on its Price-To-Earnings Ratio (148.5x) compared to the US Biotechs industry average (17.5x).

Price to Earnings Ratio vs Fair Ratio

What is GENS.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GENS.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio148.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GENS.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GENS.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$22.40
US$30.66
+36.9%
14.8%US$38.56US$23.01n/a8
Feb ’26US$22.20
US$30.66
+38.1%
14.8%US$38.56US$23.01n/a8
Jan ’26n/a
US$30.88
0%
15.6%US$39.51US$23.58n/a7
Dec ’25US$20.90
US$33.30
+59.3%
12.5%US$39.20US$28.45n/a6
Nov ’25n/a
US$34.02
0%
12.5%US$40.05US$29.07n/a6
Oct ’25n/a
US$34.45
0%
13.4%US$40.83US$28.32n/a6
Sep ’25n/a
US$34.51
0%
12.1%US$40.13US$27.83n/a6
Aug ’25n/a
US$34.30
0%
12.7%US$40.13US$27.83n/a6
Jul ’25US$21.13
US$34.72
+64.3%
15.9%US$43.74US$28.74n/a6
Jun ’25US$22.17
US$34.72
+56.6%
15.9%US$43.74US$28.74n/a6
May ’25n/a
US$34.72
0%
15.9%US$43.74US$28.74n/a6
Apr ’25n/a
US$37.50
0%
14.7%US$44.31US$29.23n/a6
Mar ’25n/a
US$37.50
0%
14.7%US$44.31US$29.23n/a6
Feb ’25n/a
US$40.66
0%
20.9%US$55.30US$28.47US$22.206
Jan ’25n/a
US$40.66
0%
20.9%US$55.30US$28.47n/a6
Dec ’24n/a
US$40.66
0%
20.9%US$55.30US$28.47US$20.906
Nov ’24n/a
US$41.89
0%
16.7%US$55.28US$34.15n/a6
Oct ’24n/a
US$42.26
0%
18.1%US$55.78US$31.98n/a6
Sep ’24n/a
US$45.50
0%
14.9%US$57.54US$38.89n/a6
Aug ’24n/a
US$48.17
0%
17.9%US$62.05US$37.75n/a6
Jul ’24n/a
US$48.17
0%
17.9%US$62.05US$37.75US$21.136
Jun ’24n/a
US$48.17
0%
17.9%US$62.05US$37.75US$22.176
May ’24n/a
US$52.26
0%
21.2%US$74.02US$39.48n/a6
Apr ’24n/a
US$52.26
0%
21.2%US$74.02US$39.48n/a6
Mar ’24n/a
US$52.66
0%
20.9%US$72.14US$38.47n/a5
Feb ’24n/a
US$53.36
0%
17.3%US$70.82US$39.76n/a6
Analyst Price Target
Consensus Narrative from 8 Analysts
US$30.91
Fair Value
27.5% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 00:54
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genus plc is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert ChantryBerenberg
Alexander JonesBofA Global Research
Francesco GregoriCharles Stanley Securities